|
Early Drug Discovery Expected to Improve with First-of-its-Kind Mass Spectrometry Platform from Applied Biosystems/MDS ... (Business Wire via Yahoo! Finance)
FOSTER CITY, Calif.----Applied Biosystems , an Applera Corporation business, and its joint venture partner, Sciex, a division of MDS Inc.'s Analytical Technologies business, , today announced plans to commercialize a first-of-its-kind mass spectrometry platform designed to help pharmaceutical companies accelerate the drug compound screening process.
(Apr 17, 2007)
Nanogen Submits 510(K) for Cystic Fibrosis Genetic Assay and NanoChip(R) 400 System (Business Wire via Yahoo! Finance)
SAN DIEGO----Nanogen, Inc. , developer of advanced diagnostic products, announced today that it has submitted the 510 to FDA for its Cystic Fibrosis Kit and NanoChip® 400 microarray system.
(Apr 17, 2007)
Matritech to Report First Quarter 2007 Financial Results on May 1, 2007 (Business Wire via Yahoo! Finance)
NEWTON, Mass.----Matritech announced today that it will release its first quarter 2007 earnings results before market opening on May 1, 2007. The company has scheduled a conference call at 8:30 a.m. that day to discuss the results and provide a company update.
(Apr 17, 2007)
Invitrogen Garners Six Life Science Industry Awards (Business Wire via Yahoo! Finance)
CARLSBAD, Calif.----Invitrogen Corporation , a provider of essential life science technologies for disease research and drug discovery, today announced it was recognized by the life sciences industry at The Scientists' annual Life Science Industry Awards, winning in six categories.
(Apr 17, 2007)
Affymetrix and NuGEN Announce Agreement to Co-market the NuGEN WT-Ovation(TM) FFPE System (Business Wire via Yahoo! Finance)
SANTA CLARA, Calif. & SAN CARLOS, Calif.----Affymetrix Inc. and NuGEN Technologies Inc., a privately held company that develops and commercializes nucleic acid amplification and labeling systems for small and difficult samples, announced today their agreement to co-market a solution that enables researchers to access FFPE tissue samples derived from years of clinical studies previously ...
(Apr 17, 2007)
Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection (PR Newswire via Yahoo! Finance)
Findings published in the April 15th issue of Blood show that a team of researchers led by Millennium Pharmaceuticals, Inc. has discovered biomarkers which may lead to identifying multiple myeloma patients likely to respond to VELCADE.
(Apr 17, 2007)
Former Puebloans close to Virginia Tech tragedy (The Pueblo Chieftain)
As the deadliest shooting rampage in U.S. history unfolded Monday morning on the Virginia Tech campus, former Puebloan Don Mullins was in a university greenhouse doing routine research. "I was out of touch in terms of e-mail and wasn't aware of what had happened until about 10 a.m.," Mullins said in a telephone interview Monday afternoon from his home in Blacksburg, Va. Mullins is a ...
(Apr 17, 2007)
Murdock challenges researchers (Salisbury Post)
250 scientists converge on N.C. Research Campus during conference
(Apr 17, 2007)
Biosite Announces Expiration of Hart-Scott-Rodino Waiting Period for Tender Offer With Beckman Coulter (PR Newswire via Yahoo! Finance)
Biosite Incorporated today announced that the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired without a request for additional information from the U.S.
(Apr 17, 2007)
AVN944 Biomarker Study Identifies Gene Signatures Important for Patient Stratification (RedNova)
GERMANTOWN, Md., April 17 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today announced the results of an AVN944 biomarker study that utilized Avalon's proprietary AvalonRx(R) technology to identify gene signatures that may be useful for patient stratification.
(Apr 17, 2007)
Nanogen Asks FDA for Kit Approval (AP via Yahoo! Finance)
Nanogen Inc., which develops medical test products, said it asked the Food and Drug Administration to approve its cystic fibrosis test kit and the Nanochip 400 microarray system.
(Apr 17, 2007)
17 April 2007 (PharmiWeb)
Los Angeles – April 17, 2007 –DiaGenic ASA today presented prototypes for its early diagnostic test for breast cancer at the American Association for Cancer Research’s special Late-Breaking sessions at the 2007 Annual Meeting.
(Apr 17, 2007)
Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection (RedNova)
CAMBRIDGE, Mass., April 17 /PRNewswire-FirstCall/ -- Findings published in the April 15th issue of Blood show that a team of researchers led by Millennium Pharmaceuticals, Inc. has discovered biomarkers which may lead to identifying multiple myeloma patients likely to respond to VELCADE.
(Apr 17, 2007)
TFN NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 15:40 BST (Sharewatch)
AffyMetrix inks NuGEN pact SANTA CLARA, Calif. (AP) - Affymetrix Inc., which makes products used to analyze genetic information, said Tuesday it is partnering with NuGEN Technologies Inc. to market a product allowing researchers to examine genes on archived tissue samples.
(Apr 17, 2007)
Agilent Technologies Announces Clinical Data's Cogenics Division As Its First Certified Service Provider For miRNA ... (BioresearchOnline)
Agilent Technologies, Inc., and Cogenics, a division of Clinical Data, Inc., today announced that Cogenics is the first Certified Microarray Service Provider for Agilent's microRNA (miRNA) microarrays
(Apr 17, 2007)
Western avian influenza genomes sequenced (EARTHtimes.org)
A U.S.-led team of researchers has reported the first large-scale sequencing of the western genomes of the deadly avian influenza virus H5N1.
(Apr 17, 2007)
(AFX UK Focus) 2007-04-17 15:55 GMT: TFN NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 15:40 BST (Interactive Investor)
2007-04-17 14:47:03 AffyMetrix inks NuGEN pact
(Apr 17, 2007)
Biosite to Conduct First Quarter 2007 Results Conference Call (PR Newswire via Yahoo! Finance)
Biosite Incorporated announces the following webcast:
(Apr 17, 2007)
Western avian influenza genomes sequenced (UPI)
A U.S.-led team of researchers has reported the first large-scale sequencing of the western genomes of the deadly avian influenza virus H5N1. The study, led by Steven Salzberg of the University of Maryland, confirmed not only has the virus spread west
(Apr 17, 2007)
Nanogen Submits 510(K) for Cystic Fibrosis Genetic Assay and NanoChip(R) 400 System (RedNova)
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced today that it has submitted the 510(K) to FDA for its Cystic Fibrosis Kit and NanoChip® 400 microarray system.
(Apr 17, 2007)
Affymetrix and NuGEN Announce Agreement to Co-Market the NuGEN WT-Ovation(TM) FFPE System (RedNova)
Affymetrix Inc. (NASDAQ:AFFX) and NuGEN Technol
(Apr 17, 2007)
Western avian influenza genomes sequenced (Moldova.org)
A U.S.-led team of researchers has reported the first large-scale sequencing of the western genomes of the deadly avian influenza virus H5N1.The study, led by Steven Salzberg of the University of Maryland, confirmed not only has the virus spread west from Asia, but two of the new western strains have independently combined, or reassorted, to create a new strain.The research involved 36 genomes of ...
(Apr 17, 2007)
Genes and biomarkers that allow doctors to choose the right therapy for the right patient (EurekAlert!)
LOS ANGELES -- Genetic and epigenetic variations ensure that no two people are exactly alike, and the same holds true for any two cancers.
(Apr 17, 2007)
Researchers sequence western H5N1 virus genomes (PhysOrg)
In a paper in the May issue of Emerging Infectious Diseases, an international team of researchers report the first ever large-scale sequencing of western genomes of the deadly avian influenza virus, H5N1.
(Apr 17, 2007)
Genes and Biomarkers That Allow Doctors to Choose the Right Therapy for the Right Patient (Newswise)
At the 2007 Annual Meeting of the American Association for Cancer Research, researchers present new biomarkers - and techniques for determining biomarkers - that could determine how an individual might respond to drug or radiation therapy.
(Apr 17, 2007)
AACR, FDA and NCI Announce Cancer Biomarkers Collaborative at the AACR 2007 Annual Meeting (Newswise)
The American Association for Cancer Research, together with the Food and Drug Administration and National Cancer Institute, today announces the formation of the AACR-FDA-NCI Cancer Biomarkers Collaborative (CBC) to facilitate the use of validated biomarkers in clinical trials and ultimately in evidence-based oncology and cancer medicine.
(Apr 17, 2007)
State envisions BT policy, to make it strategic priority sector (Indian Express via Yahoo! India News)
GUJARAT is all set to get a biotechnology (BT) policy aimed at giving fillip to the cutting-edge sector by focusing on incentives, human resource development, and infrastructure development. Likely to be announced by in-charge Minister for Science and Technology Anandiben Patel on Wednesday, the policy would put in place a framework aimed at leveraging Gujarat s existing entrepreneurial strengths ...
(Apr 17, 2007)
Hybrigenics' Inecalcitol Shows High Level Of Tolerance (Medical News Today)
Hybrigenics announces today the first results from its Phase I clinical trial of inecalcitol, a synthetic analogue of vitamin D under development by Hybrigenics as a potential treatment for prostate cancer. Inecalcitol was administered orally in a double-blind randomized study against placebo on 36 healthy volunteers up to 80 micrograms. No side effects were observed. [click link for full article]
(Apr 17, 2007)
UCSD Cancer Researchers Report Ability to Detect Cancer at Earliest, Curable Stage (Business Wire via Yahoo! Finance)
SAN DIEGO----Researchers at the Moores Cancer Center at the University of California, San Diego report that they have developed a new method for detecting cancer very early in its development, when it consists of just a few cells.
(Apr 18, 2007)
Daily Digest (San Diego Daily Transcript via Yahoo! News)
The Daily Digest intends to help readers track major announcements made by and about companies on the San Diego Stock Exchange Index. The Daily Digest tracks announcements and SEC filings released from midnight until 4 p.m., or three hours after the stock markets close. To see how companies on the San Diego Stock Exchange Index performed, turn to Page 8A.
(Apr 18, 2007)
Genes And Biomarkers That Allow Doctors To Choose The Right Therapy For The Right Patient (Science Daily)
Genetic and epigenetic variations ensure that no two people are exactly alike, and the same holds true for any two cancers. Now, researchers have the tools and the knowledge to help predict how individuals will respond to cancer therapies, enabling them to create more effective therapies for individual cancers -- personalized medicine.
(Apr 18, 2007)
Scientists present their own ideas for research campus (Independent Tribune)
CHARLOTTE - Researchers gathered at UNC Charlotte Tuesday gave recommendations for the vision of the North Carolina Research Campus.
(Apr 18, 2007)
UCSD Cancer Researchers Report Ability to Detect Cancer at Earliest, Curable Stage (RedNova)
Researchers at the Moores Cancer Center at the University of California, San Diego report that they have developed a new method for detecting cancer very early in its development, when it consists of just a few cells.
(Apr 18, 2007)
Millennium Discovers Biomarkers Potentially Predictive Of Response To VELCADE(R) (Bortezomib) For Injection (Medical News Today)
Findings published in the April 15th issue of Blood show that a team of researchers led by Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) has discovered biomarkers which may lead to identifying multiple myeloma patients likely to respond to VELCADE. VELCADE is the U.S. market leading therapy for previously treated multiple myeloma patients with an unsurpassed median survival of 29. [click link ...
(Apr 18, 2007)
AVN944 Biomarker Study Identifies Gene Signatures Important For Patient Stratification (Medical News Today)
Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), today announced the results of an AVN944 biomarker study that utilized Avalon's proprietary AvalonRx(R) technology to identify gene signatures that may be useful for patient stratification. [click link for full article]
(Apr 18, 2007)
Macaque Genome Analysis Will Help Find Human Disease Genes (Medical News Today)
Cornell experts in computational biology and bioinformatics have made key contributions to the analysis of the genome of the rhesus macaque, better known as the rhesus monkey. The Cornell researchers were part of a consortium of some 200 scientists around the world whose work is reported in a special section of the journal Science. [click link for full article]
(Apr 18, 2007)
aTyr Pharma Completes $10.5M Series B Round (Business Wire via Yahoo! Finance)
SAN DIEGO----aTyr Pharma, a privately held biopharmaceutical company focused on identifying and developing a novel class of naturally occurring protein biologics for human therapeutics, today announced the closing of its $10.5 million Series B financing.
(Apr 18, 2007)
H5N1 western genomes sequenced (News-Medical-Net)
In a paper in the May issue of Emerging Infectious Diseases , an international team of researchers report the first ever large-scale sequencing of western genomes of the deadly avian influenza virus, H5N1.
(Apr 18, 2007)
Affymetrix to Host Conference Call on April 25, 2007 to Announce First Quarter 2007 Results (Business Wire via Yahoo! Finance)
SANTA CLARA, Calif.----Affymetrix, Inc. today announced that it will release results for the first quarter 2007 after close of the stock market on Wednesday, April 25, 2007.
(Apr 18, 2007)
Molecular Biometrics to Open Research and Development Facility in Montreal (Market Wire via Yahoo! Finance)
Molecular Biometrics, LLC, a privately held metabolomics company, today announced the opening of a research and development facility in Montreal, Quebec. Molecular Biometrics Canada, ULC, will operate and manage the facility.
(Apr 18, 2007)
Case Studies of Over 100 Non-Biotechnology/Non-Pharmaceutical Companies (Business Wire via Yahoo! Finance)
DUBLIN, Ireland----Research and Markets has announced the addition of "Comprehensive Analysis of R&D and Commercialization for Related Biotechnologies from Non-Biotechnology/Non-Pharmace Companies" to their offering.
(Apr 18, 2007)
Biosite Incorporated Receives Revised Commitment Letters From Inverness Medical Regarding Possible Merger Transaction (PR Newswire via Yahoo! Finance)
Biosite Incorporated today announced that Inverness Medical Innovations, Inc. has provided Biosite with copies of revised commitment letters from Inverness' proposed financing sources in connection with the previously announced acquisition proposal made by Inverness to acquire all of Biosite's outstanding shares of common stock, other than Biosite shares already owned by Inverness, for $90.00 ...
(Apr 18, 2007)
Biomarkers Influence on Drug Discovery and Clinical Diagnostics Continues to Expand (PR Newswire via Yahoo! Finance)
Biomarkers are being incorporated into several stages of drug discovery and development as they bear the potential to accelerate preclinical and clinical development. Furthermore, theranostic applications have penetrated the market, paving the way for the integration of biomarker applications in the diagnostics and pharmaceutical industry.
(Apr 18, 2007)
Biosite Incorporated Receives Revised Commitment Letters From Inverness Medical Regarding Possible Merger Transaction (FinanzNachrichten)
SAN DIEGO, April 18 /PRNewswire-FirstCall/ -- Biosite Incorporated ( Nachrichten ) today announced that Inverness Medical Innovations, ( Nachrichten ) Inc. has provided Biosite with copies of revised commitment letters from Inverness' proposed financing sources in connection with the previously announced acquisition proposal made by Inverness to acquire all of Biosite's outstanding shares of ...
(Apr 18, 2007)
'We introduced Kannapolis to the world' (Salisbury Post)
Researchers wind up two-day conference; Murdock goes forward with N.C. Research Campus CHARLOTTE — Visiting scientists offered some advice Tuesday for charting the future of the North Carolina Research Campus in Kannapolis.
(Apr 18, 2007)
Lumera Launches Podcast Series Featuring Experts in Nanotechnology, Bio-Arrays, Electro-Optics and Wireless Technologies (Business Wire via Yahoo! Finance)
BOTHELL, Wash.----Lumera Corporation , a leader in the emerging field of nanotechnology, announced today it would host a series of podcast interviews with industry leaders who are familiar with Lumera's technology and are experts in nanotechnology, bio-arrays, drug discovery, electro-optics, and wireless technologies.
(Apr 18, 2007)
Red Hat Teams with UNC and the North Carolina Research Campus to Bring Open Source Philosophy to Campus (Business Wire via Yahoo! Finance)
RALEIGH, N.C.----Red Hat, Inc. , the world's leading provider of open source solutions, today announced that the company would work with the University of North Carolina system and the North Carolina Research Campus to advance the adoption of open source philosophies of standards and collaboration in biotechnology, bioinformatics, public policy and healthcare research.
(Apr 18, 2007)
Thallion Presents Data at the 2007 Annual Meeting of the American Association of Cancer Research on its Oncology Drug ... (CCNMatthews via Yahoo! Finance)
MONTREAL, QUEBEC-- - Thallion Pharmaceuticals Inc. today announced that new data on its two anticancer drug candidates, ECO-4601 and CAP-232, have been presented in three poster presentations at the 98th Annual Meeting of the American Association for Cancer Research , held in Los Angeles April 14-19, 2007.
(Apr 18, 2007)
Medica Supports Minnesota Partnership (Business Wire via Yahoo! Finance)
MINNETONKA, Minn.----Medica, through its grant-making arm the Medica Foundation, has awarded $5 million to the Minnesota Partnership for Biotechnology and Medical Genomics to support three research projects in cancer and heart disease, as well as two projects to provide critical research infrastructure improvements.
(Apr 18, 2007)
Red Hat to Open Office at N.C. Research Campus (Local Tech Wire)
Raleigh — Red Hat will open an office at the North Carolina Research Campus as part of its efforts to expand use of open source solutions in biotech and life science research.
(Apr 18, 2007)
|
